Official blog
Compliance-aware guides and brand updates for adult consumers.
Page 25 of 35 / 832 articles
Nicotine addiction is physiological, but 'being a smoker' is an identity—one built over years of rituals, social bonds, and self-narratives. Quitting means not just breaking a chemical dependency, but losing a version of yourself.
Machine learning models trained on millions of quit attempts are beginning to predict—with unsettling accuracy—who will succeed, when they'll relapse, and what intervention would help most. The science of quitting is becoming a science of prediction.
For decades, the public health establishment measured success by one metric: abstinence. But what if the biggest wins come from accepting that people will continue using nicotine—and making that use dramatically safer?
Behind every brightly-colored disposable vape is a global supply chain of extraction, assembly, consumption, and waste—one that produces millions of units of electronic waste every week, with no meaningful recycling infrastructure.
When Congress gave FDA authority over tobacco-derived nicotine, it inadvertently created a multibillion-dollar market for synthetic nicotine—made in labs, free from tobacco, and for a time, free from regulation.
One hundred articles, following one hundred before them. The second series concludes—not because the nicotine story is resolved, but because every inquiry must have an ending. The work continues.
A comprehensive, evidence-based summary of where we stand on nicotine policy—the evidence, the debates, the progress, and the remaining challenges.
Two hundred articles, two series, one continuous inquiry into the nicotine landscape. This final article closes the series—not with a conclusion, but with gratitude and an invitation.
Public health communication about nicotine has prioritized simplicity over accuracy. The result is a public that doesn't understand the risk continuum—and smokers who don't know that switching could save their lives.
A statistical portrait of the tobacco epidemic: the billion smokers, the 7 million annual deaths, the trillions in economic costs. The numbers tell a story that words alone cannot.
Getting smokers from 20 cigarettes a day to 2 is a public health triumph. Getting from 2 to zero is a personal battle that policy alone can't win. The 'last mile' of smoking cessation deserves more attention.
After hundreds of articles and thousands of pages, what are the essential lessons of the nicotine debate? Ten takeaways that distill the evidence, the arguments, and the human dimensions.
One hundred more articles on nicotine. The landscape hasn't resolved—it's deepened. The evidence has accumulated, the arguments have evolved, and the central challenge remains unchanged.
From 'ENDS' to 'harm reduction' to 'PMTA,' the nicotine debate has a specialized vocabulary. Here's a glossary of key terms, with definitions that acknowledge the controversies behind them.
A concise, evidence-based briefing on the nicotine landscape, designed for the people who make the decisions. What's the evidence, what's the uncertainty, and what are the policy options?
What are the most urgent unanswered questions in nicotine science? A research agenda for the next decade, organized by the questions whose answers would most affect policy and practice.
What do nicotine users themselves think about the policies that affect them? Their voices are rarely heard in the policy debate—but they should be.
The series concludes—and the story continues. A final look forward at the forces, the evidence, and the choices that will shape the nicotine landscape in the years ahead.
The UK embraces vaping. Australia bans it. The U.S. is somewhere in between. The global nicotine regulatory landscape is fragmenting, not converging. Why—and what happens next?
Nicotine is used to treat smoking addiction—and it's the substance that causes smoking addiction. It enhances cognition and impairs development. It's the central paradox of the nicotine debate.
Nicotine use, cessation, and harm are not evenly distributed across space. From the rural smoking belt to the urban vaping hub, geography is destiny for nicotine users—and policy needs to reflect that.
Strip away the rhetoric, the institutional positions, and the statistical arguments. What are the fundamental questions at the heart of the nicotine debate? Seven questions that frame everything else.
The denormalization of smoking was a public health triumph. But it had a shadow side: the stigmatization of smokers. Shame, it turns out, is not an effective cessation strategy.
Sometimes a picture is worth a thousand words—or a thousand articles. Five data visualizations that capture the essence of the nicotine debate more clearly than any prose.
Products
Select a product to view details, highlights, and technical specifications.
